Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to on

ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma

Findings highlight opportunities for further improvement in treatment use and adherence, despite the

Guggenheim analyst Debjit Chattopadhyay maintains Pharvaris (NASDAQ:PHVS) with a Buy and raises t

Morgan Stanley analyst Maxwell Skor maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raise

Leerink Partners analyst Joseph Schwartz maintains Pharvaris (NASDAQ:PHVS) with a Outperform and

Wells Fargo analyst Yanan Zhu maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the

RBC Capital analyst Nevin Varghese maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises

Citizens analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and

Analysts cut targets for CAN, TTAN and BSX, while raising targets for BRZE, VRNS, IMAX, PHVS and CHY

Wedbush analyst Laura Chico maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the pr

U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, a

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Pharvaris (NASDAQ:PHVS) with a Buy

U.S. stocks fell Tuesday, but Roivant surged 16% on positive PH-ILD trial data. Pharvaris, Solaris,

Pharvaris (PHVS) stock surges 17% on positive Phase 3 HAE trial data. Deucrictibant XR reduced month

Gainers iSpecimen (NASDAQ:ISPC) stock increased by 22.7% to $1.89 during Tuesday's pre-market s

Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only p

RBC Capital analyst Brian Abrahams maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises

Guggenheim analyst Debjit Chattopadhyay maintains Pharvaris (NASDAQ:PHVS) with a Buy and raises t

Citizens analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and

Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.81) per share which missed the analyst cons

Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor

Wells Fargo analyst Yanan Zhu initiates coverage on Pharvaris (NASDAQ:PHVS) with a Overweight rat

If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE att

Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and r

Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 recept

Citizens analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and

Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.69) per share which beat the analyst consen

All shares in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the under

Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2

Wolfe Research analyst Andy Chen initiates coverage on Pharvaris (NASDAQ:PHVS) with a Outperform

Wedbush analyst Laura Chico maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the pr

Pharvaris enrolled deucrictibant XR for HAE in CHAPTER 3. Positive results could lend 30% upside to

RBC Capital analyst Brian Abrahams maintains Pharvaris (NASDAQ:PHVS) with a Outperform and lowers

Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.84) per share which missed the analyst cons

Results from Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, provide evidence of viability of brad

Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights in

RBC Capital analyst Brian Abrahams initiates coverage on Pharvaris (NASDAQ:PHVS) with a Outperfor

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Pharvaris (NASDAQ:PHVS) with a Buy

RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance

Oppenheimer analyst Justin Kim maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the

Guggenheim analyst Debjit Chattopadhyay maintains Pharvaris (NASDAQ:PHVS) with a Buy and raises t

Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and r

B of A Securities analyst Tazeen Ahmad maintains Pharvaris (NASDAQ:PHVS) with a Neutral and raise

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Pharvaris (NASDAQ:PHVS) with a Buy

Pharvaris reports Phase 3 data showing its oral HAE treatment delivers rapid relief, fewer second do

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly f

Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and r